Antibody responses to AZD1222 vaccination in West Africa

Adam Abdullahi; David Oladele; Steven Kemp; James Ayorinde; Abideen Salako; Fehintola Ige; Douglas Fink; Chika Onwuamah; Qosim Osuolale; Rufai Abubakar; Azuka Okuruawe; Gideon Liboro; Oluwatosin Odubela; Gregory Ohihoin; Oliver Ezechi; Olagoke Usman; Sunfay Mogaji; Adedamola Dada; Soraya Ebrahimi; Lourdes Ceron Gutierrez; Sani H Aliyu; Rainer Doffinger; Rosemary Audu; Richard Adegbola; Petra Mlcochova; Babatunde Lawal Salako; Ravindra K Gupta.
Preprint en Inglés | PREPRINT-MEDRXIV | ID: ppmedrxiv-22274668

Documentos relacionados

  1. Trends of humoral immune responses to heterologous antigenic exposure due to vaccination & omicron SARS-CoV-2 infection: Implications for boosting.
  2. Humoral immune response after different SARS-CoV-2 vaccination regimens.
  3. SARS-COV-2 antibody responses to AZD1222 vaccination in West Africa.
  4. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization.
  5. Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial.
  6. ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19.
  7. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
  8. Presence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies Among Vietnamese Healthcare Workers by Dosing Interval for ChAdOx1 nCoV-19 Vaccine.
  9. Effects of the second dose of COVID-19 vaccines in patients with autoimmune rheumatic diseases with hybrid immunity.
  10. Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials.